MedPath

HopeMed's HMI-115 Shows Promise in Endometriosis-Associated Pain Treatment

• HopeMed's HMI-115, a prolactin inhibitor, demonstrates potential as a first-line treatment for endometriosis-associated pain, according to interim Phase II results. • The international Phase II study has bolstered HopeMed's confidence in HMI-115's ability to address this chronic disorder. • The company anticipates that HMI-115 could provide a novel approach to managing pain associated with endometriosis.

Hope Medicine is optimistic that its drug candidate, HMI-115, a prolactin-inhibiting antibody, could become a first-line treatment for endometriosis-associated pain. Interim results from an international Phase II study have increased the company's confidence in the drug's potential to address this chronic condition.
Endometriosis is a condition in which tissue similar to the lining of the uterus grows outside of it, causing pain and infertility. Current treatments often involve hormone therapies or surgery, which can have significant side effects or may not be suitable for all patients. There is a significant unmet need for effective and well-tolerated treatments for endometriosis-associated pain.
HMI-115 is designed to inhibit prolactin, a hormone that plays a role in various reproductive processes. By inhibiting prolactin, HMI-115 aims to reduce the growth and inflammation of endometrial tissue outside the uterus, thereby alleviating pain. The ongoing Phase II study is evaluating the safety and efficacy of HMI-115 in women with endometriosis-associated pain. The interim results suggest that HMI-115 is showing promise in reducing pain symptoms.
Hope Medicine is a Chinese venture focused on developing innovative therapies for unmet medical needs. The company is committed to advancing HMI-115 through clinical development and bringing a new treatment option to women with endometriosis-associated pain.
Subscribe Icon

Stay Updated with Our Daily Newsletter

Get the latest pharmaceutical insights, research highlights, and industry updates delivered to your inbox every day.

Related Topics

EnteroBiotix Completes Phase 2 Trial Recruitment of EBX-102-02 for Irritable Bowel Syndrome

EnteroBiotix has completed recruitment for its Phase 2 TrIuMPH trial, which is evaluating EBX-102-02 in 122 patients with moderate to severe irritable bowel syndrome (IBS).
The trial includes patients with both constipation-predominant IBS (IBS-C) and diarrhea-predominant IBS (IBS-D), with 62 and 60 participants respectively.

HMI-115: Novel Endometriosis Drug Allows Pregnancy During Treatment

HMI-115, a new drug for endometriosis, significantly reduces pain and uniquely allows patients to become pregnant during treatment.
The drug works by blocking a protein produced in response to endometriosis, addressing a long-standing need for hormone-bypassing pain relief.

Levicept's LEVI-04 Shows Positive Phase II Results in Osteoarthritis

Levicept's LEVI-04 met its primary endpoint in a Phase II trial, demonstrating significant pain reduction in patients with moderate to severe osteoarthritis.
The study showed significant improvements across all measured osteoarthritis symptoms and signs for all doses of LEVI-04 tested.

Hope Medicine's HMI-115 Shows Promise in Phase 2 Endometriosis Trial

Hope Medicine's HMI-115, a first-in-class monoclonal antibody, significantly reduced endometriosis-associated pain in a Phase 2 trial.
The study reported a 42% reduction in mean dysmenorrhea pain and a 50% reduction in non-menstrual pelvic pain with HMI-115.

Gut Microbiome Imbalance Linked to Endometriosis Risk, Suggesting New Diagnostic and Therapeutic Avenues

Researchers have identified a unique gut microbiome profile in women with endometriosis, characterized by a deficiency in the bacterial byproduct 4-hydroxyindole.
The study suggests that stool tests could be developed to predict a woman's risk of endometriosis, potentially leading to earlier diagnosis.

EDAP TMS Announces First Patients Treated in Phase I/II Study of Focal One HIFU for Benign Prostatic Hyperplasia

EDAP TMS has initiated a Phase I/II clinical trial evaluating Focal One robotic HIFU for benign prostatic hyperplasia (BPH) treatment.
The study aims to determine optimal treatment parameters using Focal One HIFU to improve BPH symptoms with minimal side effects.

Anakinra Shows Promise in Reducing Endometriosis-Related Pain and Inflammation in Pilot Study

A pilot study suggests that anakinra, an IL-1 antagonist, may reduce dysmenorrhea pain scores in women with endometriosis.
The study also found statistically significant improvements in quality of life, specifically in the domains of powerlessness and self-image.

Hamlet BioPharma's Phase II Trial Shows Immunotherapy Matches Antibiotics for Cystitis

Hamlet BioPharma's Phase II trial demonstrates that anakinra immunotherapy achieves similar clinical outcomes to antibiotics in treating recurrent acute cystitis.
The study showed significant symptom reduction, fewer recurrences, and improved quality of life for patients treated with both anakinra and antibiotics.

Endo's Collagenase Clostridium Histolyticum Shows Promise in Phase 2 Plantar Fibromatosis Study

Endo presented Phase 2 clinical trial data of collagenase clostridium histolyticum (CCH) for plantar fibromatosis at the AOFAS annual meeting.
The study demonstrated a trend toward pain reduction with CCH treatment compared to placebo, as measured by the Foot Function Index.

Ensifentrine Shows Promise in Improving Lung Function and COPD Symptoms

A Phase 2b trial of ensifentrine demonstrated statistically significant improvements in lung function in COPD patients.
The study also met clinically relevant secondary endpoints, showing improvements in COPD symptoms.

Reference News

[1]
HopeMed Hopes For First-Line Inroads In Endometriosis-Associated Pain - Citeline
insights.citeline.com · Nov 18, 2024

HopeMed's Phase II study interim results with prolactin inhibiting antibody HMI-115 boost confidence in first-line poten...

© Copyright 2025. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy